Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.

Background: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outcome framework spanning surgical, renal, infectious, and oncologic domains. Methods: Searches of PubMed/MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, Scopus, and CINAHL retrieved comparative studies (randomized controlled trials, prospective and retrospective cohorts, case-control studies) reporting RARN versus LRN outcomes in adults with high-complexity renal tumors. Screening, data extraction, and risk-of-bias assessment were performed independently in duplicate. Pooling used DerSimonian-Laird random-effects meta-analysis. Heterogeneity was quantified using I² and 95% prediction intervals. Evidence certainty was graded with GRADE. A total of 22 studies encompassing 4,163 patients (RARN: 1,748; LRN: 2,415) met inclusion criteria. Results: RARN was associated with a significantly lower conversion rate to open surgery (odds ratio [OR] 0.38, 95% CI 0.21-0.68; I²=11%; moderate-certainty evidence), reduced estimated blood loss (mean difference [MD] -81.4 mL, 95% CI -112.3 to -50.5; I²=48%), lower transfusion rate (OR 0.54, 95% CI 0.35-0.84), and superior eGFR preservation (MD +3.2 mL/min/1.73 m², 95% CI 0.8-5.6). Operative time was longer in the RARN group (MD +22.7 min, 95% CI 9.3-36.1). No statistically significant differences emerged in overall complication rate, major complication rate, positive surgical margin rate, or recurrence-free survival; however, RARN was associated with a modestly shorter length of stay. Subgroup analysis demonstrated the greatest RARN advantage in IVC thrombus cases (Mayo level III-IV) and tumors ≥10 cm. Conclusions: Among adults undergoing radical nephrectomy for high-complexity renal tumors, RARN confers a meaningful reduction in conversion to open surgery, intraoperative blood loss, transfusion requirement, and acute renal functional loss compared with LRN, at the cost of modestly longer operative time. Evidence quality is moderate for the primary outcome and low-to-moderate for secondary endpoints, reflecting a predominantly observational evidence base. A dedicated randomized controlled trial in the T3-T4 and IVC thrombus subpopulation remains the priority for future research.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-06-24
DOI
https://doi.org/10.7417/ct.2026.2086
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.

Sarah Abdelrahman Mohammed, Hayat Mahmoud Mahmoud, Md Hasan Sharif, Osama M. Ghoneimy et al.
PubMed
Renal cell carcinoma treatment
article

Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.

Sarah Abdelrahman Mohammed, Hayat Mahmoud Mahmoud, Md Hasan Sharif, Osama M. Ghoneimy, Mohamad Adel Abdalgaleel, Khaled Asem Allam, Khalid Alaghbar, Mohamed Elnemr, Ayman Abdelmonem Ahmed Kayed, Gameel Aboelgheit, Mennat Allah Oda, Saher Elshazly, Thamer Mhanna, Taher Rezk, Mohammad Albachaan
article en

Abstract

Background: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outcome framework spanning surgical, renal, infectious, and oncologic domains. Methods: Searches of PubMed/MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, Scopus, and CINAHL retrieved comparative studies (randomized controlled trials, prospective and retrospective cohorts, case-control studies) reporting RARN versus LRN outcomes in adults with high-complexity renal tumors. Screening, data extraction, and risk-of-bias assessment were performed independently in duplicate. Pooling used DerSimonian-Laird random-effects meta-analysis. Heterogeneity was quantified using I² and 95% prediction intervals. Evidence certainty was graded with GRADE. A total of 22 studies encompassing 4,163 patients (RARN: 1,748; LRN: 2,415) met inclusion criteria. Results: RARN was associated with a significantly lower conversion rate to open surgery (odds ratio [OR] 0.38, 95% CI 0.21-0.68; I²=11%; moderate-certainty evidence), reduced estimated blood loss (mean difference [MD] -81.4 mL, 95% CI -112.3 to -50.5; I²=48%), lower transfusion rate (OR 0.54, 95% CI 0.35-0.84), and superior eGFR preservation (MD +3.2 mL/min/1.73 m², 95% CI 0.8-5.6). Operative time was longer in the RARN group (MD +22.7 min, 95% CI 9.3-36.1). No statistically significant differences emerged in overall complication rate, major complication rate, positive surgical margin rate, or recurrence-free survival; however, RARN was associated with a modestly shorter length of stay. Subgroup analysis demonstrated the greatest RARN advantage in IVC thrombus cases (Mayo level III-IV) and tumors ≥10 cm. Conclusions: Among adults undergoing radical nephrectomy for high-complexity renal tumors, RARN confers a meaningful reduction in conversion to open surgery, intraoperative blood loss, transfusion requirement, and acute renal functional loss compared with LRN, at the cost of modestly longer operative time. Evidence quality is moderate for the primary outcome and low-to-moderate for secondary endpoints, reflecting a predominantly observational evidence base. A dedicated randomized controlled trial in the T3-T4 and IVC thrombus subpopulation remains the priority for future research.

PubMedVol. 177(4)
Beni-Suef University (EG), North Bristol NHS Trust (GB), Al-Azhar University (EG), Zagazig University (EG), Benha University (EG), London North West Healthcare NHS Trust (GB), Milton Keynes Hospital (GB), Luton and Dunstable Hospital (GB), King Abdullah International Medical Research Center (SA), Warrington and Halton Teaching Hospitals NHS Foundation Trust (GB), Mersey Care NHS Trust (GB), Ministry of Health (AE), General Organization For Teaching Hospitals and Institutes (EG), Royal Manchester Children's Hospital (GB)
Openalex Percentile: Top 7%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.